PKCα regulates platelet granule secretion and thrombus formation in mice

Department of Physiology & Pharmacology, School of Medical Sciences, University of Bristol, Bristol, United Kingdom.
Journal of Clinical Investigation (Impact Factor: 13.22). 02/2009; 119(2):399-407. DOI: 10.1172/JCI34665
Source: PubMed


Platelets are central players in atherothrombosis development in coronary artery disease. The PKC family provides important intracellular mechanisms for regulating platelet activity, and platelets express several members of this family, including the classical isoforms PKCalpha and PKCbeta and novel isoforms PKCdelta and PKCtheta. Here, we used a genetic approach to definitively demonstrate the role played by PKCalpha in regulating thrombus formation and platelet function. Thrombus formation in vivo was attenuated in Prkca-/- mice, and PKCalpha was required for thrombus formation in vitro, although this PKC isoform did not regulate platelet adhesion to collagen. The ablation of in vitro thrombus formation in Prkca-/- platelets was rescued by the addition of ADP, consistent with the key mechanistic finding that dense-granule biogenesis and secretion depend upon PKCalpha expression. Furthermore, defective platelet aggregation in response to either collagen-related peptide or thrombin could be overcome by an increase in agonist concentration. Evidence of overt bleeding, including gastrointestinal and tail bleeding, was not seen in Prkca-/- mice. In summary, the effects of PKCalpha ablation on thrombus formation and granule secretion may implicate PKCalpha as a drug target for antithrombotic therapy.

Download full-text


Available from: Judith M. Cosemans,
  • Source
    • "The initial evidence for SNAP23 came from a permeabilized platelet system, in the same study as the STX2 and STX4 results described above (Chen et al, 2000a,b; Lemons et al, 2000). There is also evidence for protein kinase C (PKC)-mediated SNAP23 phosphorylation occurring simultaneously with secretion in platelets (Polgar et al, 2003; Konopatskaya et al, 2009), but the same was previously shown for STX4, which was subsequently proven to be redundant in secretion (Chung et al, 2000). More recently, the protein kinase IKK (IjB kinase) was shown to mediate phosphorylation of SNAP23, which in turn was shown to be important for SNARE complex formation, but the effects of an IKK inhibitor on other SNAREs were not evaluated, so it cannot be concluded that SNAP23 is the only SNARE undergoing this modification (Karim et al, 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Upon activation by extracellular matrix components or soluble agonists, platelets release in excess of 300 active molecules from intracellular granules. Those factors can both activate further platelets and mediate a range of responses in other cells. The complex microenvironment of a growing thrombus, as well as platelets' roles in both physiological and pathological processes, require platelet secretion to be highly spatially and temporally regulated to ensure appropriate responses to a range of stimuli. However, how this regulation is achieved remains incompletely understood. In this review we outline the importance of regulated secretion in thrombosis as well as in 'novel' scenarios beyond haemostasis and give a detailed summary of what is known about the molecular mechanisms of platelet exocytosis. We also discuss a number of theories of how different cargoes could be released in a tightly orchestrated manner, allowing complex interactions between platelets and their environment.
    British Journal of Haematology 11/2013; 165(2). DOI:10.1111/bjh.12682 · 4.71 Impact Factor
  • Source
    • "Although, a certain redundancy in activator signaling by PKCα and β may exist in human platelets, studies have shown PKCα to be essential for α-granule release, while PKCβ may be more important in regulating α IIb β 3 signaling during aggregation (Buensuceso et al., 2005; Gilio et al., 2010; Yoshioka et al., 2001). PKCα has been shown to be essential for α-granule release by permeabilized human platelets (Yoshioka et al., 2001), and PKCα null mice have substantially impaired release of α-granule contents upon aggregation (Konopatskaya et al., 2009). Although "
    [Show abstract] [Hide abstract]
    ABSTRACT: Platelets promote angiogenesis by releasing angiogenesis-regulating factors from their α-granules upon aggregation. This effect has both physiological and pathological significance as it may contribute to carcinogenesis. Platelet α-granule release and aggregation are regulated, in part, via PKCα and β signaling. Therefore the purpose of our study was to investigate the effects of PKC inhibition on aggregation, angiogenesis-regulator secretion from α-granules and platelet-stimulated angiogenesis. We hypothesized that selective PKCα inhibition may preferentially suppress angiogenesis-regulator secretion from α-granules, but not aggregation, limiting platelet-stimulated angiogenesis. Human platelets were aggregated in the presence conventional PKC inhibitors myr-FARKGALRQ and Ro 32-0432. Immunofluorescence microscopy of PKC translocation was used to determine the specificity of PKC-inhibitor targeting. ELISA was used to measure vascular endothelial growth factor (VEGF) and thrombospondin-1 (TSP-1) release from platelets. Platelet effects on angiogenesis were tested using a capillary-formation assay. Ro 32-0432, but not the peptide inhibitor myr-FARKGALRQ, inhibited aggregation in a concentration-dependent manner, while both Ro 32-0432 and myr-FARKGALRQ preferentially suppressed VEGF over TSP-1 secretion. Suppression of angiogenesis-regulator release occurred at inhibitor concentrations that did not signifcantly affect aggregation. Immunofluorescence microscopy revealed that PKCα targeting to α-granules is inhibited when angiogenesis-regulator secretion is uncoupled from aggregation. At concentrations that uncoupled α-granule release from aggregation, Ro 32-0432 and myr-FARKGALRQ inhibited platelet-stimulated angiogenesis. Hence, selective PKCα inhibition suppresses angiogenesis-regulator release from platelet α-granules with minimal effects on aggregation. Thus, selective PKCα inhibitors may have pharmacological significance to regulate platelet-promoted angiogenesis.
    Journal of Pharmacology and Experimental Therapeutics 02/2013; 345(1). DOI:10.1124/jpet.112.200881 · 3.97 Impact Factor
  • Source
    • "Subcellular morphology of wild-type and RhoF−/− platelets was analysed by transmission electron microscopy (TEM). Ultrathin counterstained sections were prepared as previously described [20]. Mouse platelets were pelleted from platelet rich plasma as described above. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Formation of filopodia and other shape change events are vital for platelet hemostatic function. The mechanisms regulating filopodia formation by platelets are incompletely understood however. In particular the small GTPase responsible for initiating filopodia formation by platelets remains elusive. The canonical pathway involving Cdc42 is not essential for filopodia formation in mouse platelets. The small GTPase Rif (RhoF) provides an alternative route to filopodia generation in other cell types and is expressed in both human and mouse platelets. We hypothesized that Rif might be responsible for generating filopodia by platelets and generated a novel knockout mouse model to investigate the functional role of Rif in platelets. Constitutive RhoF(-/-) mice are viable and have normal platelet, leukocyte and erythrocyte counts and indices. RhoF(-/-) platelets form filopodia and spread normally on various agonist surfaces in static conditions and under arterial shear. In addition, RhoF(-/-) platelets have normal actin dynamics, are able to activate and aggregate normally and secrete from alpha and dense granules in response to collagen related peptide and thrombin stimulation. The small GTPase Rif does not appear to be critical for platelet function in mice. Functional overlap between Rif and other small GTPases may be responsible for the non-essential role of Rif in platelets.
    PLoS ONE 01/2013; 8(1):e54663. DOI:10.1371/journal.pone.0054663 · 3.23 Impact Factor
Show more